Today: 25 January 2026
Subscribe
Browse Category

NASDAQ:AZN News 10 January 2026 - 11 January 2026

AstraZeneca stock: Nasdaq-100 exit date nears as index flows and JPM conference loom

AstraZeneca stock: Nasdaq-100 exit date nears as index flows and JPM conference loom

London, Jan 11, 2026, 16:43 GMT — Market closed. AstraZeneca shares head into Monday’s session under pressure after Nasdaq announced Walmart will take the drugmaker’s spot in the Nasdaq-100 starting Jan. 20. (Reuters) This is significant today since index trackers often translate a calendar shift into actual trades. Funds following the Nasdaq-100 usually tweak their holdings near the effective date,…
11 January 2026
······
AstraZeneca stock set for Nasdaq-100 exit on Jan. 20 as Walmart takes its slot — what AZN investors watch next

AstraZeneca stock set for Nasdaq-100 exit on Jan. 20 as Walmart takes its slot — what AZN investors watch next

New York, January 10, 2026, 14:04 EST — Market closed AstraZeneca PLC’s U.S.-listed shares will exit the Nasdaq-100 on Jan. 20, with Walmart stepping in as its replacement, Nasdaq announced Friday. Walmart revealed in November plans to shift its listing from the New York Stock Exchange to Nasdaq. (Reuters) This matters since the Nasdaq-100 is closely followed by index funds…
10 January 2026
······

Stock Market Today

  • Concerns Raised Over Responsive Industries Limited's Price-to-Earnings Ratio Amid Slower Earnings Growth
    January 24, 2026, 9:50 PM EST. Responsive Industries Limited (NSE:RESPONIND) trades at a price-to-earnings (P/E) ratio of 21.3x, close to India's market median of 23x. Despite an 8.6% earnings per share (EPS) growth last year, its three-year growth remains stagnant, trailing behind the broader market's expected 26% growth next year. This disconnect raises concerns that the current P/E may not be justified by fundamentals, risking a price decline if earnings continue to disappoint. Investors holding the stock may face downside pressure, while prospective buyers should be cautious about paying a premium given the company's underwhelming medium-term growth prospects.
Go toTop